Nasdaq GlobeNewswire

LogicBio Therapeutics to Present Preclinical Data at European Society of Gene & Cell Therapy 25th Anniversary Congress in Berlin

Del

· Company co-founder Professor Adi Barzel, Ph.D., to present new proof-of-concept efficacy data

CAMBRIDGE, Massachusetts, Oct. 16, 2017 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc., a gene-therapy company with a mission to develop cures for early-onset life-threatening diseases, announced today that its company co-founder, Dr. Adi Barzel, will present new data from its genome-editing platform during the 25th Annual European Society of Gene & Cell Therapy (ESGCT) Congress in two presentations this Wednesday in Berlin, Germany. The ESGCT will be held from October 17-20, 2017, at the bcc Berlin.

Dr. Barzel will present data in multiple animal models of disease demonstrating the extended therapeutic potential of LogicBio's proprietary GeneRide(TM) platform technology. The GeneRide technology harnesses the natural power of homologous recombination to enable precise, site-specific in vivo genome editing to deliver therapeutic genetic material without the use of vector-borne promoters or nucleases.

 "We are very excited to present proof-of-concept efficacy data in models of multiple genetic diseases and to demonstrate the breadth and the versatility of our GeneRideTM technology," said LogicBio President and CEO Fred Chereau. "We also feel fortunate developing our platform technology with world-renowned academic collaborators, enabling us to advance development candidates for early onset life-threatening diseases rapidly - from the benchtop into the clinic."

Due to the genomic editing feature, LogicBio's GeneRideTM technology has shown in preclinical studies that it can provide stable therapeutic levels of life-saving proteins after a single injection. It overcomes a major challenge of the conventional gene therapy in pediatric indications - dilution of therapeutic benefit due to the proliferation of cells in the growing tissue of a child. Thus, the GeneRide technology is uniquely suitable to treat many rare, early-onset and severe genetic diseases.

LogicBio presentations at the ESGCT Congress are as follows:

Oral Presentation

Title: GeneRide(TM): Therapeutic in vivo gene targeting without nucleases

Session: Gene Editing I

When: October 18, 2017, 2:40 p.m. CEST

Room: C01

Poster Presentation

Title: GeneRide(TM): Therapeutic in vivo gene targeting without nucleases

When: October 18, 2017, 6:50 p.m. CEST

Abstract Number: P129

A co-founder of LogicBio, Dr. Barzel is the president elect of the Israeli Society of Gene and Cell Therapy and a senior lecturer (associate professor) at the Department of Biochemistry at Tel Aviv University. Dr. Barzel has a research background in homologous recombination and gene targeting. He is a Summa cum Laude graduate of the Adi Lautman interdisciplinary program for outstanding students, and has earned his PhD in genetics from the laboratory of Professor Martin Kupiec at Tel Aviv University. Previously, Major Adi Barzel was a company commander in an armor brigade and in the officer's academy of the Israeli Defense Forces. He invented the GeneRide technology during his time as a postdoctoral fellow at the Kay Lab at Stanford Medicine, Stanford University. He has co-authored scientific papers in high-impact journals describing the GeneRide technology and its applications.

About LogicBio Therapeutics (www.logicbio.com; twitter: @logicbio)

A preclinical-stage company with a mission to develop cures for life-threatening diseases, LogicBio combines the best of gene therapy and genome-editing technology. Founded by gene-therapy pioneers from leading academic institutions including Stanford University, Tel Aviv University, and Children's Medical Research Institute in Sydney - the company's core platform includes its proprietary GeneRide technology and synthetic gene-therapy vectors derived from naturally occurring human adeno-associated viruses. LogicBio designed its approach to harness the natural power of homologous recombination - enabling precise, site-specific transfer of the genetic material without the use of vector-borne promoters or nucleases, which could be associated with unwanted side effects. The goal: provide patients with a functional version of a faulty, disease-causing gene to deliver a cure. LogicBio is advancing programs for rare, life-threatening pediatric genetic diseases - focusing first on inborn errors of metabolism, where there are few, if any, treatment options. A number of the company's discoveries have been featured in leading science publications and conferences. A private company, LogicBio is based in Cambridge, Massachusetts, with a research group in Tel Aviv.


Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/21431f6d-93d7-4c5f-a5d1-1a51641c6b2f

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/81511cac-ee28-4f0e-add0-dcceb0ea0a5c

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/95980a56-cec5-4e55-850b-a5f2a1713159

Caroline Grossman
LogicBio Therapeutics, Inc.
(781) 771.5579
caroline@mirepoixllc.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LogicBio Therapeutics, Inc. via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Northland Power Announces Retirement of CEO John Brace and Appointment of Mike Crawley as Chief Executive Officer, Effective August 4, 201823.5.2018 01:27Pressemelding

TORONTO, May 22, 2018 (GLOBE NEWSWIRE) -- Northland Power Inc. ("Northland") (TSX:NPI) today announced that Chief Executive Officer John Brace will retire on August 4, 2018 after 30 years with the company. Mike Crawley, currently Northland's Executive Vice President, Development has been appointed to the role of Chief Executive Officer, effective August 4, 2018. Mr. Brace and Mr. Crawley will work together to ensure a smooth transition. Mr. Brace will continue to serve as a Director of Northland. John joined Northland in 1988, shortly after the company was founded. He was appointed Chief Executive Officer in 2005. He has steered Northland through many of its projects, initiatives and growth. Under his leadership, the company has grown to its current enterprise value of $12 billion. John was appointed to Northland's Board of Directors on April 4, 2018, and along with Northland's other board members, will stand for re-election at Northland's Annual General Meeting on May 23rd, 2018. Mike

MyoGen: Leaders of an Anabolic Revolution22.5.2018 23:00Pressemelding

GUJARAT, India, May 23, 2018 (GLOBE NEWSWIRE) -- Myogen will make you rethink what the human body is capable of. To be an athlete means to partake on a never-ending quest for self-improvement. An obsession to search for a winning edge. Even when we are competing against ourselves, our desire to overcome our physical limitations and achieve new heroic and record setting performances becomes an overwhelming primary focus. Today marks an evolution in what the human body is capable of, with the launch of the MyoGen range of anabolic products. Myogen, the essence of "muscles". MyoGen takes its source from the Greek words "Myo" meaning "Muscle" and "Genesis" meaning "Birth". This implicit historical reference, of the origin of the muscle, displays both the commitment and professionalism of Myogen, and their unwavering focus on peak physical performance. The brightest leader's blaze trails. The Myogen brand is managed by an international team of experts who are committed to making athletes st

Constellation Brands Promotes Jim Sabia to Newly Created Role of Chief Marketing Officer22.5.2018 22:30Pressemelding

New role will serve as a member of the company's Executive Management Committee VICTOR, N.Y., May 22, 2018 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE:STZ) (NYSE:STZ.B), a leading beverage alcohol company, announced today that it has promoted Jim Sabia to the newly created role of Executive Vice President and Chief Marketing Officer, Constellation Brands. In this new role, Sabia will serve as the marketing lead for the company's Beer and Wine & Spirits Divisions, responsible for all aspects of marketing across Constellation's entire beverage alcohol portfolio. Sabia will serve as a member of the company's Executive Management Committee and report directly to Bill Newlands, President and Chief Operating Officer. "Our company's core mission is to build brands consumers love and Jim has been a driving force behind the success of our beer brands over the years," said Newlands. "It is critically important that the voice of the consumer and brand-building principles have strong repr

Algeco Announces First Quarter 2018 Financial Results Conference Call22.5.2018 17:52Pressemelding

BALTIMORE, May 22, 2018 (GLOBE NEWSWIRE) -- Algeco Investments B.V. (together with its subsidiaries, "Algeco"), the leading global business services provider of modular space, secure portable storage solutions and remote workforce accommodations, today announced that it will hold its first quarter 2018 financial results conference call on Tuesday, June 5, 2018 at 10:00 a.m., Eastern Time. To access the call, please dial (847) 585-4422 or (888) 424-8151 (US toll free) and enter participant PIN code 9192211# approximately ten minutes prior to the start of the call. You will be placed on hold until the event begins. The conference call will also be broadcast over the internet with an accompanying slide presentation. To join the web conference, go to http://web.meetme.net/r.aspx?p=2&a=UTzMrdwdRriEIu. Please enter your name, email address and company to join the call. The customer service team can be reached at any time by pressing *0 on your telephone keypad. On Wednesday, May 30, 2018 at

Hitachi Named a Visionary in Inaugural Gartner Magic Quadrant for Industrial IoT Platforms22.5.2018 15:00Pressemelding

Hitachi Positioned in Visionaries Quadrant for Completeness of Vision and Ability To Execute TOKYO and SANTA CLARA, Calif., May 22, 2018 (GLOBE NEWSWIRE) -- Hitachi, Ltd. (TSE:6501) and Hitachi Vantara, today announced that Hitachi has been positioned in the Visionaries quadrant of the inaugural Gartner Magic Quadrant for Industrial IoT Platforms1based on Gartner, Inc.'s evaluation of the company, which included Hitachi's Lumada IoT platform. Gartner describes the market for IIoT platforms as "a set of integrated software capabilities. These capabilities span efforts to improve asset management decision-making, as well as operational visibility and control for plants, depots, infrastructure and equipment within asset-intensive industries." In the report, Gartner predicts: "By 2020, on-premises Internet of Things (IoT) platforms coupled with edge computing will account for up to 60% of industrial IoT (IIoT) analytics, up from less than 10% today." The report also notes: "Gartner believe

Oxford Immunotec Announces Launch of the Accutix(TM) Brand22.5.2018 14:30Pressemelding

OXFORD, United Kingdom and MARLBOROUGH, Mass., May 22, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced the launch of the Accutix brand for its tick-borne disease offering. "Incorporating the feedback of our customers was a key consideration in our selection of a new brand name," said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. "Tick-borne disease specialists value the accuracy of our tests and the history and credibility of our lab in helping them diagnose Lyme and other tick-borne diseases. The Accutix name embodies these qualities and will assist us in building a market leadership position in the tick-borne disease diagnostics market." The Accutix brand aligns Oxford Immunotec's tick-borne disease offering, which includes over 20 testing options targeting eight tick-borne diseases, under a unified name. The Company will continue to develop new assays for both existing and emergin

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom